Categories

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma August 25, 2026 Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, establishing a new standard of care in front-line GEA Company to host […]

To learn more about the latest data from TAGRISSO, visit the website here. Please see full Prescribing Information, including Patient Information for TAGRISSO. TAGRISSO is a registered trademark of the AstraZeneca group of companies. ©2025 AstraZeneca.    All rights reserved.    US-105694   Last Updated 10/25

Based on TROPION-Lung05 results and supported by data from TROPION-Lung01 First and only TROP2-directed therapy approved in the US for the treatment of lung cancer DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and […]

IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer Based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death vs. neoadjuvant chemotherapy alone AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and […]

AstraZeneca has announcedthat the US Food and Drug Administration (FDA) has approved a new indication for IMFINZI, in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC). Approval was based on results from […]

On January 17, 2025, the US Food and Drug Administration (FDA) approved DATROWAY® (datopotamab deruxtecan-dlnk) for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or […]

This live virtual meeting is being hosted by the Alabama Cancer Congress, Mississippi Oncology Society, and the Oklahoma Society of Clinical Oncology. Date: Wednesday, January 15, 2025 Zoom Meeting 6:00 PM – 7:00 PM CT Meeting ID: 865 1269 7774Passcode: 677092 Speaker: Matthew D. Galsky, MDProfessor of MedicineIcahn School of Medicine at Mount Sinai Director […]

Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been approved in the US for the treatment of adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) and no known epidermal […]

Nursing Statistics and Trends You Need to Know: https://www.registerednursing.org/articles/50-nursing-statistics/

Based on three Phase II trials of AstraZeneca and Daiichi Sankyo’s Enhertu which showed clinically meaningful responses across a broad range of tumours Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of […]